EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Neuropathy

Theodoros Panou, Evanthia Gouveri, Djordje S Popovic iD, Dimitrios Papazoglou, Nikolaos Papanas iD

Experimental and Clinical Endocrinology & Diabetes · 01.08.2025 · 133 (08) · 425-436

DOI: 10.1055/a-2640-9411 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.08.2025. Verfasst von Theodoros Panou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Greece. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Neuropathies, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic neuropathy is a serious complication of diabetes mellitus (DM). Its commonest manifestation is diabetic peripheral neuropathy (DPN). Diabetic neuropathy may also affect the autonomic nervous system, cardiac autonomic neuropathy (CAN) being its most widely studied manifestation. Treatment of DPN and CAN relies on glycaemic control and symptom alleviation, emphasizing the need for improvement. To this purpose, the novel antidiabetic oral agents sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have been studied. Beyond their favourable effects on metabolic control and cardiovascular and renal outcomes, these agents appear to harbour some beneficial actions in DPN and CAN as well. The underlying mechanisms are not entirely clear, but appear to involve the 5' adenosine monophosphate-activated protein kinase (AMPK)-pathway. So far, clinical experience has been limited. Significant improvement in electrophysiological parameters and thermal perception has been observed among subjects with type 2 diabetes mellitus (T2DM) in small studies. However, contradictory findings have also been reported. The same ambiguous effect of SGLT-2is has been observed in CAN. Thus, future large studies are required to delineate the utility of SGLT-2is in DPN and/or CAN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic NeuropathiesDiabetes Mellitus, Type 2Hypoglycemic AgentsHumans

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Greece.
  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia.

ORCID-Profile: Djordje S Popovic, Nikolaos Papanas

Zitieren

APA

Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Papanas, N. (2025). The Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Neuropathy. Experimental and Clinical Endocrinology & Diabetes, 133(08), 425-436. https://doi.org/10.1055/a-2640-9411

Vancouver

Panou T, Gouveri E, Popovic DS, Papazoglou D, Papanas N. The Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Neuropathy. Experimental and Clinical Endocrinology & Diabetes. 2025;133(08):425-436. doi:10.1055/a-2640-9411

BibTeX
@article{Panou2025,
  author = {Panou, Theodoros and Gouveri, Evanthia and Popovic, Djordje S and Papazoglou, Dimitrios and Papanas, Nikolaos},
  title = {The Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Neuropathy},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2025},
  volume = {133},
  number = {08},
  pages = {425--436},
  doi = {10.1055/a-2640-9411}
}
Kostenlos starten →